Immunic, Inc. · NASDAQ:IMUX
Immunic — Corporate Update (February 2021)
115 slides from Immunic's corporate update, Feb 26, 2021
Slide 1: Slide 1
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 216 of the Securities
Slide 3: Our Vision
Our Vision We are developing new therapies with best-in-class potential for the treatment of chronic inflammatory and autoimmune diseases. 3. | ©immunic, inc. | Feb/26/2021 & |mmunic
Slide 4: Key Investment Highlights: Broad Value-Generating Pipeline
Key Investment Highlights: Broad Value-Generating Pipeline = Successfully demonstrated robust efficacy and excellent safety/tolerability in RRMS phase 2 trial Lead PI ac ly ® Clinical activity demonstrated in COVID-19 and primary sclerosing cholangitis = Phase 2 trial in patients with ulcerative col
Slide 5: Leadership Team
Leadership Team Company is Led by an Experienced Brey Renowned International NACA 7 Management Team Samm Board of Directors Daniel Vitt, Duane Nash, Duane Daniel Vitt, Ny PhD I MD, JD, MBA ~ Nash, MD, ie. PhD oy CEO & President 2) Executive Chairman 2 JD, MBA “ ceEO& ecutive President of y re Chairm
Slide 6: Development Pipeline
Development Pipeline IMU-856 Gastrointestinal Diseases Intestinal Barrier Function Program | Indication Target Preclinical Phase 1 Phase 2 Phase 3 Imu-838 Multiple Sclerosis DHODH —— Uleerative Colitis DHODH $$ Crohn's Disease DHODH —_[—_ Primary Sclerosing Cholangitis | DHODH [UII LT LT) eee honein
Slide 7: Mode of Action: DHODH Targeting Leads to Metabolic Stress
Mode of Action: DHODH Targeting Leads to Metabolic Stress in Metabolically Hyperactivated Cells Lymphocyte Activated Lymphocyte pyri CY "recycling “Stressed” Lymphocyte IMU-838 + © Disease related activation Metabolically silent DHODH not important ‘Adapted from Tan etal, 2016, MolCell 62 7 | ©immun
Slide 8: Slide 8
Slide 9: MS Disease Course
MS Disease Course!) tt Treatment Compliance and Persistence are Important Considerations for Life-Long Diseases such as MS Preclinical | Relapsing-remitting Clinical disability fit tit tt Secondary progressive phase |. _ Brain volume asia - MRI activity il i lx? years >|<— 10-15 years —>|<—— 20 + ye
Slide 10: Despite Many Therapies Approved, There Remains Ample Opportunity
Despite Many Therapies Approved (and Nearing Approval) for Relapsing Forms of MS, There Remains Ample Opportunity fora ... Safe Oral Well-Tolerated Robust Anti-Inflammatory, with Neuroprotective Properties Beyond What Would be Expected by Reducing Inflammation.
Slide 11: EMPhASIS: Phase 2 Study Overview in RRMS
EMPhASIS: Phase 2 Study Overview in RRMS NCT03846219 Included Patient Population: 5) RRMS With Relevant Disease Activity = Male or female ( 18 > age < 55) P Coordinating Investigator = RRMS diagnosis (Revised McDonald criteria 2017) = Evidence of disease activity based on relapse and MRI criteria =
Slide 12: EMPhASIS: Phase 2 Trial Design in RRMS
EMPhASIS: Phase 2 Trial Design in RRMS | _ 300r45 mg 30 mg IMU-838 — EoMT 30 mg IMU-838 ad aes EoT 30 or 45 mg 45 mg IMU-838 — EoMT 45 mg IMU-838 nahn EoT Scr. BLMRI = or 45 mg exam. Placebo — EoMT alk 30mgIMU-838 — “ity Sage EoT 30 0145 mg 45 mg IMU-838 noneens EoT l | | | | | D-28 D-14 DO W24/EoMT
Slide 13: Slide 13
Slide 14: Study Met Primary and Key Secondary Endpoints
Study Met Primary and Key Secondary Endpoints 120 peopoee Robust efficacy on demonstrated 80 for both - 62% investigated reduction doses of 40 IMU-838 with oo highstatistical significance. 0 30mg/day 45mg/day Suppression of CUA MRI Lesions IMU-838 versus Placebo over 24 weeks ‘CUAMRI Lesions: combin
Slide 15: Study Results 1: Robust Efficacy
Study Results 1: Robust Efficacy The Robust MRI Lesion Suppression of IMU-838 Compares Favorably to Other First-Line and Oral Base Medications Commercially Available in RRMS.* IMu-838 IMu-838 Giana: | etimenatteen|| Stein Rtagettaedl®? || Staarthaaels acetatelt] fumarate!) Administration Oral Oral I
Slide 16: Time to Relapse
Time to Relapse Kaplan Meier Analysis 1.00 0.78. i Proportion of patients without relapse up to Week 24 oso 0.25 Patients 68 7 64 64 63 6 6 59 i 2 atrisk 65 6a et 59 87 sr 58 54 2 4 0.00. 85 63 62 Ed 35 53 50 ry i 0 0 10 2 30 4 50 60 70 8 9 100 110 120 130 140 150 160 170 160 190 200 210 Time to rel
Slide 17: Unconfirmed Disability Progression up to Week 24
Unconfirmed Disability Progression up to Week 24 Proportion of patients with unconfirmed EDSS progression Despite the to Week 24) D ; ene (up to Week 24) study’s relatively 15.0% small sample 40.0% size and short 2% duration of — blinded 25.0% 23.1% 20.0% treatment (24 15.0% 11.8% 12.1% weeks), a 10
Slide 18: Neurofilament Light Chain in Serum
Neurofilament Light Chain in Serum Biomarker for Axonal Damage € 2+ : Robust decrease 4 in serum s 7 Se 46.5% neurofilament as ° light chain 7 ee 7205 % provides Bo evidence of 3 | potential By | neuroprotective . | activity for ia 4 : IMU-838. 30 mg IMU-838 45 mg IMU-838 Placebo Treatment group ‘Qu
Slide 19: Slide 19
Slide 20: Overall Treatment Discontinuations
Overall Treatment Discontinuations a Randomized Patients N=210 alee Treatment Discontinuation Before Week 24 (All Dosed Patients Until End of Blinded Treatment) gard eonaans Placebo 7.2% 5/69 Nel All IMU-838 43% 6/140 SS 30 mg IMU-838 2.8% 2/71 pag 7 Ee 45 mg IMU-838 5.8% 4/69 Placebo 30 mg IMU-838
Slide 21: Study Results 2: Low Discontinuation Rates
Study Results 2: Low Discontinuation Rates Low Discontinuation Rates for IMU-838 Treated RRMS Patients, Considerably Lower Than Placebo, Indicate an Overall Encouraging Tolerance Profile While Providing a Sense of Efficacy to Patients.* IMu-838 IMu-838 Chita: mentee) EI! | sometime! || inentimedle a
Slide 22: Overall Rate of Patients With Treatment-Emergent Adverse Events
Overall Rate of Patients With Treatment-Emergent Adverse Events Treatment Group Number of TEAE lesan a 30 mg IMU-838 70 32/71 (45.1%) 45 mg IMU-838 59 28/69 (40.6%) Placebo 62 30/69 (43.5%) There were three patients with serious treatment-emergent adverse events (SAE) in this trial: ‘EAE: treatment-
Slide 23: Most Common Treatment-Emergent Adverse Events
Most Common Treatment-Emergent Adverse Events Adverse Events Present in More Than 1% of Study Population 30 mg IMU-838 25 mg IMU-838 Placebo Total Number Number Number Number fwumber| of [PM lumber] of [PEM lumber] of [PENI number| of | [Patents ‘of TEAE| Patients | of TEAE| Patients | of TEAE| Pati
Slide 24: Treatment-Emergent Adverse Events: Infections and Infestations
Treatment-Emergent Adverse Events: Infections and Infestations 30 mg IMU-838 45 mg IMU-838 Placebo: Total |TEAE of SOC: lInfections and [Number of| Number of | Number of| Number of| infestations fyumberof| Patients |P2%"*5|yumberof] Patients |°3t2M"SIvumberof] Patients [°°] wumberof] Patients [Patie
Slide 25: Absence of Hepatotoxicity Signals
Absence of Hepatotoxicity Signals Hy’s Law Assessment for Drug-Induced Liver Injury Hy’s Law Assessment (ALT) 10 Absence of Hepatotoxicity Signals and Other Relevant Adverse Events Leading to Discontinuations Differentiates Against Other Available Oral RRMS Medications. Liver Enzyme Elevations Peak
Slide 26: IMU-838 Positioned to be a New Safe and Efficacious Treatment Option
IMU-838 Positioned to be a New Safe and Efficacious Treatment Option for Early RRMS Patients IMU-838 Could Provide RRMS Patients With a Distinctive Combination of Robust Efficacy Combined With Favorable Safety and Tolerability due to Uniquely Blending of Properties: Robust MRI lesion suppression of
Slide 27: IMU-838 in RRMS: Further Development Plan
IMU-838 in RRMS: Further Development Plan (al Completion of Phase 2 Data Set Preparation of a Phase 3 Program = Double-blind Cohort 2 sub-trial ongoing to obtain = Formal phase 3 feasibility activities already ongoing exploratory data on expanded dose response of IMU-838: = Formal end-of-phase 2 mee
Slide 28: IMU-838 in RRMS: Market and Positioning
IMU-838 in RRMS: Market and Positioning Full Prescription Coverage by Payers Achievable IMU-838 Compared with First-Line and Oral Medications in RRMS for IMU-838 at an Attractive Pricing Range 18% i x 7 o = "a 2 Si nod IMU-838 = Historically, innovator brands with a differentiated profile have not o
Slide 29: Slide 29
Slide 30: IBD: Therapeutic Pyramid
IBD: Therapeutic Pyramid fl Current Solutions Have Limitations = Substantial side effects due to long-term Selective use includes increased rate of cancer risk Immunomodulators and virus reactivation of currently used Moderate Traditional Immunomodulators immunosuppressants/! (21 (31 Corticosteroids
Slide 31: IMU-838: Key Strengths That Address Limitation of Existing Therapies in IBD
IMU-838: Key Strengths That Address Limitation of Existing Therapies in IBD TS No clinical evidence of increased rate of viral reactivations — in-vitro data of direct antiviral effect Mode of action may provide a new treatment option for patients failing other therapies in IBD Small molecule with lo
Slide 32: ENTRANCE Study: Primary Efficacy Results
ENTRANCE Study: Primary Efficacy Results Number of Patients 5) Non- ENTRANCE Study: a Partial Responders Responders (11.5%) = Study performed with active a5 =a (34.6%) moiety vidofludimus * 7 Total Response 14 BERG All patients flled two attempts to taper down steroids Complete BEY Oven-label, dosin
Slide 33: CALDOSE-1: Clinical Phase 2 in UC Ongoing
CALDOSE-1: Clinical Phase 2 in UC Ongoing NCT03341962 @ & QX\ Coordinating Investigator: Dr. Geert d’Haens (AMC Amsterdam) Active IND in the United States Overall Number of Patients: 240 Currently More Than 100 Active Sites in 14 Countries: USA, Western, Central and Eastern Europe IND: investigation
Slide 34: CALDOSE-1: Phase 2 Trial Design in UC
CALDOSE-1: Phase 2 Trial Design in UC Placebo (n=60) > — Placebo (n=60) Optional 10 mg IMU-838 gd a ner (n=60) Patients with Open EIS symptomatic Suse eee see > 10mg IMU-838 qd period to 30mg IMU-838 ad at weeks alsin tere (a) HOG term safety: upto 9 years + 30mg IMU-838 qd 45 mg IMU-838 qd (n=60) 1
Slide 35: CALDOSE-1: Interim Analysis Established Potentially Broad Effective Dose Range
CALDOSE-1: Interim Analysis Established Potentially Broad Effective Dose Range = Performed by an unblinded data review committee (DRC) in August 2019 = Analysis based on all available clinical, endoscopic, (2) aS biomarker, pharmacodynamic, and safety data Main Treatment Period The interim analysis
Slide 36: Slide 36
Slide 37: IMU-838 Antiviral Activity Against SARS-CoV-2 and Other Viruses
IMU-838 Antiviral Activity Against SARS-CoV-2 and Other Viruses 37 | ©immunic, inc. | Feb/26/2021 IMU-838 is active against SARS-CoV-2 IMU-838 has shown broad- spectrum antiviral activity against different pathogenic viruses with ECso values in single digit uM range HCV (ECsy 4.6 UM) rs * IMU-838 bs
Slide 38: IMU-838: Host Cell Based Approach Active Against Different Virus Variants
IMU-838: Host Cell Based Approach Active Against Different Virus Variants IMU-838 was not yet tested against different mutant forms of SARS-CoV-2, but due to its host-based mechanism, mutations are not expected to have any impact on IMU-838’s activity. = Viruses in general rely on the host cells inf
Slide 39: Anticipated Pharmacokinetic Profile 22.5 mg BID
Anticipated Pharmacokinetic Profile 22.5 mg BID 14-day Treatment in Phase 2 IMU-838 in COVID-19 Patients SARS-CoV-2 AS49-ACE2 a Proposed dosing regimen ensures that therapeutic * FCsse levels of s ete en IMU-838 are i —_ reached starting o 123 4 5 6 7 8 9 1011 2 13 14 15 16 17 18 19 20 from first do
Slide 40: CALVID-1: Study Flow Chart
CALVID-1: Study Flow Chart NCT04379271 45 mg IMU-838 (22.5 mg BID) exam. Placebo D-1 DO D14 D28 D60 BID: bis in die=two times daily; D:day;EoS: end of study; Scr: screening; exam. examination; SFU: safety followup ‘Stratification for randomization donefor age category 265 years, <65 years) and antiv
Slide 41: Slide 41
Slide 42: Proportion of Patients with Clinical Recovery
Proportion of Patients with Clinical Recovery IMU-838 Increases the Number of Patients Achieving Clinical Recovery Proportion of Patients With Clinical Recovery (Based on Symptoms Body Temperature, IMU-838 Placebo Respiratory Frequency and Blood Oxygenation) N % N % Day7 15 18.5 10 12.8 Day 28 57 71
Slide 43: Time to Clinical Improvement
Time to Clinical Improvement IMU-838 Shows Acceleration of Time to Clinical Improvement MFAS Population) ren | wee | ream | aes” (Centrally Calculated) | (P2¥S) (Days) wee 50% 13.9 13.9 0.0 75% 15.0 17.9 29 90% 18.9 26.8 79 Probability of clinical improvement 10 15 20 25 30 Days MPlacebo mIMU-838 Cl
Slide 44: Proportion of Patients with Clinical Improvement (Elderly Patients)
Proportion of Patients with Clinical Improvement (Elderly Patients) IMU-838 Increases the Number of Elderly Patients (>65 Years) Achieving Clinical Improvement Proportion of Patients With Improvement of WHO Nine-Category Ordinal Scale by at Least IMU-838 Placebo Two Points (Based on Investigator Ass
Slide 45: Decrease of SARS-CoV-2 Viral Load
Decrease of SARS-CoV-2 Viral Load Day 14 Day 28 Absolute decrease of SARS-CoV-2 = viral load (calculated as viral load at Visit Day minus viral load at oy IMU-838 Baseline Visit) An anti-viral effect of IMU-838 on SARS-CoV-2 was observed as represented by viral titers at the end of the treatment per
Slide 46: Decrease of C-Reactive Protein (CRP)
Decrease of C-Reactive Protein (CRP) Systemic Inflammation Marker Strongly Associated with Patient Outcomes* "TERRE & Info 8 2 4 aay An anti-inflammatory effect of IMU-838 was observed, based on a more effective reduction of C-reactive protein (CRP), a well-known marker for systemic inflammation in
Slide 47: Decrease of D-Dimer
Decrease of D-Dimer COVID-19 Prognostic Disease Marker Strongly Associated With Patient Outcomes* MIMU-838 ™ Placebo 0% -10% -15% 20% -25% -30% -35% in % of baseline 40% Day1 Day 6 Day14 Day 28 Amore effective reduction of D-dimer, a well-known prognostic disease marker for COVID-19, was observed in
Slide 48: Post Hoc Analysis on 'Long COVID' Symptoms
Post Hoc Analysis on ‘Long COVID’ Symptoms Initial Signal That IMU-838 May Contribute to Prevention of Long-Term Fatigue = Questionnaires from 36 patients were returned Proportion of Patients with Fatigue from investigators who participated in this trial at Study Completion at 3 clinical sites soo —
Slide 49: Summary of the Overall Rate of Adverse Events
Summary of the Overall Rate of Adverse Events No General Safety Signals, as Compared to Placebo 45 mg IMU-838 Placebo Total Number | N°-°' | patients | Number | NO-9f | patients | number | NO-°' | patients of AEs ca Te | WithAE | of AEs Sah Te | WithAE | of AEs San ne | With AE (N#) (%) (N#) (%) (N#
Slide 50: Activity on Clinical Endpoints in Hospitalized COVID-19 Patients
Activity on Clinical Endpoints in Hospitalized COVID-19 Patients IMU-838 Could Provide Moderate COVID-19 Patients a Safe and Convenient Oral Treatment Option IMU-838 showed evidence of clinical activity on multiple clinical endpoints in hospitalized patients with moderate COVID-19 | IMU-838 \ Treatm
Slide 51: Slide 51
Slide 52: IMU-838 in PSC: Phase 2 Proof-of-Concept Study
IMU-838 in PSC: Phase 2 Proof-of-Concept Study NCT03722576 wie Principal Investigator Investigator-Sponsored Trial Conducted at Two Mayo Clinic Sites Elizabeth Carey, MD (Mayo Clinic) Study Timelines = Study started in August 2019 = Enrollment took place between July 2019 and September 2020, but alm
Slide 53: Slide 53
Slide 54: Primary Objective: Change in Serum Alkaline Phosphatase
Primary Objective: Change in Serum Alkaline Phosphatase The Primary Objective Was to Determine Whether IMU-838 Reduces Serum ALP in Adult Patients Diagnosed With PSC Definition of the primary objective: postive Outcome 95% Cl = Patients who achieve a reduction of ALP Ns) at week 24 ALP Reduction >25
Slide 55: Quantitative Change in Serum Alkaline Phosphatase
Quantitative Change in Serum Alkaline Phosphatase The Primary Objective Was to Determine Whether IMU-838 Reduces Serum ALP in Adult Patients Diagnosed With PSC = Time from baseline: calculated as continuous variable and treated as the primary predictor using a random intercept model which was Sees e
Slide 56: Individual ALP Changes Over Treatment Period
Individual ALP Changes Over Treatment Period ALP at three time points = Consistent individual pattern of a stable decrease in e004 Pasar ALP values between baseline and Week 24 (24-week = mutor treatment period) 2 = musa 3 penis = While the decrease in ALP values was moderate, no a = muro7 patient o
Slide 57: Ulcerative Colitis Clinical (UCC) Score
Ulcerative Colitis Clinical (UCC) Score Physician Assessment of Ulcerative Colitis Activity The UCC score, a modification and simplification of the well- known Mayo Score, consists of four items: = stool frequency, = rectal bleeding, = subject’s functional assessment, and = physician’s global assess
Slide 58: Short Inflammatory Bowel Disease Questionnaire (SIBDQ)
Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Patient-Reported Questionnaire for Health-Related Quality of Life Questionnaire Provides a Score Ranging From 10 (Lowest The SIBDQ consists of questions scored in Score) to 70 (Highest Score) four domains: = bowel symptoms, = emotional health, =
Slide 59: IMU-838 in PSC: Outlook
IMU-838 in PSC: Outlook As an Orally Available DHODH Inhibitor With a Prominent Influence on Th17 Induced Inflammatory Processes, IMU-838 is a Promising Approach for the Treatment of PSC The encouraging results regarding biochemical parameters and safety suggest that IMU-838 merits further clinical
Slide 60: IP Position of IMU-838: Several Layers of IP
IP Position of IMU-838: Several Layers of IP ) IMU-838 is Protected by Several Layers of Patents Patent on the specific salt form and pharmaceutical composition of IMU-838, granted in the United States, Europe and other key markets — expires in 2031 New patent filed in 2018 on the specific polymorph
Slide 61: Slide 61
Slide 62: Autoimmune Diseases and IMU-935
Autoimmune Diseases and IMU-935 . 2 : Unmet Need in Psoriasis Care IL-17 in Autoimmune Diseases * Autoimmune diseases are frequent diseases affecting millions of patients worldwide) = Th17/IL-17/RORyt axis is important in auto immunity related diseases") * Antibodies targeting this axis successfully
Slide 63: IMU-935: Cytokine Inhibition in Low Nanomolar Range
IMU-935: Cytokine Inhibition in Low Nanomolar Range Effect of the Development Compound IM105935 (IMU-935) in Stimulated Human PBMC ES Inhibition of RORy(20 nM) and DHODH (240 nM) leads to synergistical inhibition of cytokines with ICsp of 3-5 nM in stimulated human lymphocytes IC59(uM) IL-I7A 0.005
Slide 64: IMU-935 Maintains Normal Thymocyte Maturation and Retains Basal Activity of RORyt
IMU-935 Maintains Normal Thymocyte Maturation and Retains Basal Activity of RORyt Thymocyie__ a maiueion Method = Sorted murine DN thymocytes were cultured on OP9-DL4 fibroblasts with mouse IL-7 for 72 hours and treated in parallel with IMU-935 Result = IMU-935 allows normal thymocyte maturation fro
Slide 65: IMU-935: Phase 1 Study Performed in Australia
IMU-935: Phase 1 Study Performed in Australia 65 | ©immunic, inc. | Feb/2 Double-blind, placebo-controlled clinical phase 1 study performed by Immunic subsidiary in Australia started in September 2019 Phase 1 study performed in three parts = Part A: Single ascending dose (SAD) study in healthy volun
Slide 66: IMU-935: Pharmacokinetic Results of Single Ascending Dose
IMU-935: Pharmacokinetic Results of Single Ascending Dose Dose-Linear AUC 1000.0 10.0 Plasma Concentration (ng/mb) Preliminary data AUC: area underthe cure;SDD: spre dried dispersion; hours; Cmax: manimum (peak plasma drug concentration; Tmax: time toreach maximum (peak) plasma concentration; AUC-in
Slide 67: IMU-935: Pharmacokinetic Modeling of Multiple Dose
IMU-935: Pharmacokinetic Modeling of Multiple Dose 120.00 Prediction of multiple dose pharmacokinetics a HLT EEEEA EEE EERE EEE I | (75 mg IMU-935 BID) 5 000 | | | | | | i Estimated accumulation a : factor for multiple a0 dosing 1.22 000 6a == ICgpIL-27, IFNY 200.00 Time (h) 50.00 400.00 BID: bis in
Slide 68: Slide 68
Slide 69: Concept of IMU-856: Restoring the Intestinal Barrier Function
Concept of IMU-856: Restoring the Intestinal Barrier Function Without Impairing the Immune System a Fo Increased Bowel Permeability Connects the Microbiome and the Immune System Picture takenfrom hizp//vibrantbiueols.com/essenti-olletohest-ancseal-the-guy) 69 | ©immunic, inc. | Feb/2 & !mmunic
Slide 70: IMU-856's Target: An Epigenetic Regulator
IMU-856’s Target: An Epigenetic Regulator... .. influencing the tightly regulated network of genes and proteins associated with epithelial cell interaction/adhesion through its enzyme activities. Gene expression Cellular functions Protein function Protein activity 70 | ©immunic, inc. | Feb/26/2021.
Slide 71: IMU-856: Hypothesis of Therapeutic Approach
IMU-856: Hypothesis of Therapeutic Approach Compartmentalize Microbiome and Immune System © by Strengthening the Bowel Barrier Function Microbiota Immune System 595 Focus on Immunosuppression Influencing the Microbiome = Changes in nutrition are driving the increase in disease rates = Diversity of m
Slide 72: IMU-856: Development Concept
IMU-856: Development Concept 72 | ©immunic, inc. | Feb/2 Exclusive global rights to commercialization of IMU-856 in all countries obtained through option and licensing agreement with Daiichi Sankyo Double-blind, randomized, placebo-controlled clinical phase 1 study performed by Immunic subsidiary in
Slide 73: Slide 73
Slide 74: Summary and Highlights
= ) Summary and Highlights Excellent phase 2 datain RRMS: IMU-838 met all statistical endpoints and underlined favorable safety and tolerability profile ofa Advanced and well-balanced pipeline Additional clinical activity of IMU demonstrated in COVID-19 and PSC; favorable safety and tolerability pro
Slide 75: Thank You!
Thank You! Immunic AG Immunic, Inc. Grafelfing (Munich) 1200 Avenue of the Americas Germany New York City, NY 10036 USA ts = Immunic Research GmbH === A Weinberg Campus Halle (Saale) Germany Immunic Australia Pty. Ltd. “Melbourne Australia 7S | ©immunic, inc. | Feb/26/2021
Slide 76: Immunic, Inc.
Immunic, Inc. 1200 Avenue of the Americas, Suite 200 Head of IR & Communications NewYork, NY 10036,,USA Phone: +49 89 2080 477 09 ® www.imux.com Email: ir@imux.com 76 | ©immunic, inc. | Feb/26/2021 © Immunic
Slide 77: Slide 77
Slide 78: IMU-838: Pipeline in a Pill
IMU-838: Pipeline in a Pill Broad Therapeutic Potential Driven by Medical Needs 78 | ©immunic, inc. | Feb/26 Relapsing-Remitting Multiple Sclerosis Ulcerative Colitis Primary Sclerosing Cholangitis COVID-19 IMU-838 is Intended to be a selective once-daily medication for RRMS patients with a well-bal
Slide 79: IMU-838 Binds to DHODH and Inhibits DHODH
IMU-838 Binds to DHODH and Inhibits DHODH IMU-838 Binds Into the DHO and Ubiquinone IMU-838 Exhibits High Species Selectivity, Most Binding Pocket Potent on Human DHODH With ICsp of “160 nM DHODH Inhibition -Hhal | _ numa monkey fret at deg amity mouse Left: Gaumgarmer etal, J. Med. Chem, 206;49:123
Slide 80: Free Acid Form
Free Acid Form Developed by 4SC cal trials were done by 4SC with a free acid formulation of the active moiety videfludimus as an amorphous material. In total, 4SC’s clinical trial data encompasses more than 250 individuals treated with the active moiety, thus creating a safety database for further I
Slide 81: Slide 81
Slide 82: Slide 82
Slide 83: Slide 83
Slide 84: Slide 84
Slide 85: Slide 85
Slide 86: Slide 86
Slide 87: Slide 87
Slide 88: Slide 88
Slide 89: Slide 89
Slide 90: Slide 90
Slide 91: Slide 91
Slide 92: Slide 92
Slide 93: Slide 93
Slide 94: Slide 94
Slide 95: Slide 95
Slide 96: Slide 96
Slide 97: Slide 97
Slide 98: Slide 98
Slide 99: Slide 99
Slide 100: Slide 100
Slide 101: Slide 101
Slide 102: Slide 102
Slide 103: Slide 103
Slide 104: Slide 104
Slide 105: Slide 105
Slide 106: Slide 106
Slide 107: Slide 107
Slide 108: Slide 108
Slide 109: Slide 109
Slide 110: Slide 110
Slide 111: Slide 111
Slide 112: Slide 112
Slide 113: Slide 113
Slide 114: Slide 114
Slide 115: Slide 115